Amanote Research

Amanote Research

    RegisterSign In

Focus on PCSK9 Inhibitors: From Genetics to Clinical Practice

Postgraduate Medicine - United Kingdom
doi 10.1080/00325481.2016.1208895
Full Text
Open PDF
Abstract

Available in full text

Categories
Medicine
Date

July 14, 2016

Authors
Marc S. SabatineJames A. UnderbergMichael KorenSeth J. Baum
Publisher

Informa UK Limited


Related search

Pcv118 - Factors Determining Selection of Appropriate Patients for Pcsk9 Inhibitors in European Clinical Practice

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

The Capabilities of Angiotensin Converting Enzyme Inhibitors in Clinical Practice: Focus on Vasoprotection

Rational Pharmacotherapy in Cardiology
Cardiovascular MedicinePharmacologyCardiology
2007English

PCSK9 Peptide Inhibitors

Science-Business eXchange
2014English

The New Genetics and Clinical Practice

Journal of Medical Genetics
Genetics
1992English

Are PCSK9 Inhibitors Cost Effective?

PharmacoEconomics
Health PolicyPublic HealthOccupational HealthPharmacologyEnvironmental
2018English

PCSK9 Inhibitors: When Statins Aren't Enough

Prescriber
Pharmacology
2017English

Clinical Practice Guidelines for Translating Pharmacogenomic Knowledge to Bedside. Focus on Anticancer Drugs

Frontiers in Pharmacology
Pharmacology
2014English

Molecular Genetics in Clinical Practice II (Retina)

Acta Ophthalmologica
MedicineOphthalmology
2018English

Bringing Prostate Cancer Germline Genetics Into Clinical Practice

Journal of Urology
Urology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy